MA50188A - Nouveaux complexes polypeptidiques bispécifiques - Google Patents

Nouveaux complexes polypeptidiques bispécifiques

Info

Publication number
MA50188A
MA50188A MA050188A MA50188A MA50188A MA 50188 A MA50188 A MA 50188A MA 050188 A MA050188 A MA 050188A MA 50188 A MA50188 A MA 50188A MA 50188 A MA50188 A MA 50188A
Authority
MA
Morocco
Prior art keywords
polypeptidic
complexes
new bispecific
bispecific
new
Prior art date
Application number
MA050188A
Other languages
English (en)
Inventor
Jing Li
Zhuozhi Wang
Jianqing Xu
Original Assignee
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Ireland Ltd
Publication of MA50188A publication Critical patent/MA50188A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050188A 2017-09-22 2018-09-20 Nouveaux complexes polypeptidiques bispécifiques MA50188A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017103030 2017-09-22

Publications (1)

Publication Number Publication Date
MA50188A true MA50188A (fr) 2021-06-02

Family

ID=65810646

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050188A MA50188A (fr) 2017-09-22 2018-09-20 Nouveaux complexes polypeptidiques bispécifiques

Country Status (19)

Country Link
US (2) US11845796B2 (fr)
EP (1) EP3684805A4 (fr)
JP (3) JP7387611B2 (fr)
KR (2) KR102839644B1 (fr)
CN (2) CN117843810A (fr)
AU (2) AU2018334886B2 (fr)
BR (1) BR112020005676A2 (fr)
CA (1) CA3075693A1 (fr)
EA (1) EA202090812A1 (fr)
IL (3) IL326091A (fr)
MA (1) MA50188A (fr)
MX (2) MX2020003145A (fr)
MY (1) MY202919A (fr)
PH (1) PH12020550112A1 (fr)
SA (1) SA522440090B1 (fr)
SG (1) SG11202002261VA (fr)
TW (1) TWI786188B (fr)
WO (1) WO2019057122A1 (fr)
ZA (1) ZA202002338B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3023551T3 (en) 2016-03-25 2025-06-02 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
CN109563166B (zh) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
EP3511340B1 (fr) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Hétérodimère fc-fusionné cytokine et composition pharmaceutique le comprenant
AU2018241881B2 (en) 2017-03-27 2024-10-10 Biomunex Pharmaceuticals Stable multispecific antibodies
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
CN109535257B (zh) 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
EP4578507A3 (fr) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions et procédés pour l'ingénierie des lymphocytes t
JP7734075B2 (ja) * 2018-12-24 2025-09-04 サノフイ 疑似ｆａｂベースの多重特異性結合タンパク質
BR112021012631A2 (pt) * 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
EP3917969A4 (fr) * 2019-01-28 2023-02-01 Wuxi Biologics Ireland Limited Nouveaux complexes polypeptidiques cd3/cd20 bispécifiques
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
CN114144429B (zh) * 2019-07-16 2023-10-13 上海药明生物技术有限公司 针对pd-1和lag-3的双特异性抗体
GB201912681D0 (en) * 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
CA3149939A1 (fr) * 2019-09-06 2021-03-11 Stephen J. Demarest Proteines comprenant des domaines constants de recepteur de lymphocytes t
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
MX2022006676A (es) 2019-12-04 2022-07-05 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
EP4086281A4 (fr) * 2019-12-30 2024-02-14 China Immunotech (Beijing) Biotechnology Co., Ltd Récepteur star de lymphocytes t amélioré et son application
EP4089111A4 (fr) 2020-01-09 2023-10-04 Jiangsu Hengrui Medicine Co., Ltd. Nouveau complexe polypeptidique
US20250263466A1 (en) 2020-02-03 2025-08-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
CN115551894A (zh) 2020-03-12 2022-12-30 以明生物免疫医疗公司 新型抗lilrb4抗体和衍生产物
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2021203053A1 (fr) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunothérapie ciblant une région conservée dans des coronavirus sras
CN115734969A (zh) * 2020-04-13 2023-03-03 上海药明生物技术有限公司 双特异性抗体的纯化
BR112022020706A2 (pt) 2020-04-14 2022-11-29 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
JP2023524669A (ja) 2020-04-26 2023-06-13 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 改変免疫グロブリン
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
PH12022500020A1 (en) 2020-05-08 2024-05-06 Vir Biotechnology Inc Antibodies against sars-cov-2
WO2021247925A1 (fr) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Immunothérapie guidée par une structure dirigée contre le sars-cov-2
EP4165077A1 (fr) 2020-06-12 2023-04-19 VIR Biotechnology, Inc. Thérapies à base d'anticorps contre une infection à sars-cov-2
WO2021253335A1 (fr) * 2020-06-18 2021-12-23 深圳迈瑞生物医疗电子股份有限公司 Anticorps anti-sous-type cd14 soluble, kit et utilisation correspondante
WO2022045247A1 (fr) * 2020-08-27 2022-03-03 学校法人順天堂 Anticorps bispécifique calr-cd3 mutant anti-tronqué et composition pharmaceutique
BR112023005684A2 (pt) 2020-09-28 2023-11-07 Humabs Biomed Sa Anticorpos contra sars-cov-2
WO2022079036A1 (fr) 2020-10-13 2022-04-21 Almirall, S.A. Molécules bispécifiques et procédés de traitement les utilisant
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
PH12023551390A1 (en) 2020-11-23 2023-12-04 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
KR20230135569A (ko) 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
CA3199429A1 (fr) 2020-11-23 2022-05-27 Davide Corti Anticorps contre la grippe et combinaisons de ces derniers
JP2023550785A (ja) 2020-11-25 2023-12-05 ヴィア・バイオテクノロジー・インコーポレイテッド 複数のベータコロナウイルスに結合する抗体
WO2022133592A1 (fr) * 2020-12-21 2022-06-30 Zymeworks Inc. Constructions tcr stabilisées et procédé d'utilisation
CN118221804B (zh) * 2021-01-18 2025-02-07 上海药明合联生物技术有限公司 工程化抗体和包含工程化抗体的抗体-药物偶联物
WO2022156687A1 (fr) * 2021-01-19 2022-07-28 Wuxi Biologics (Shanghai) Co., Ltd. Complexes polypeptidiques ayant une stabilité et une expression améliorées
TWI830124B (zh) * 2021-01-19 2024-01-21 大陸商上海藥明生物技術有限公司 具有改善的穩定性和表現的多肽複合物
AU2022215712A1 (en) * 2021-02-07 2023-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody
CN112961245B (zh) * 2021-02-24 2023-07-25 重庆精准生物技术有限公司 一种靶向cd96的双特异性抗体及其制备方法和用途
WO2022204202A1 (fr) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Anticorps qui se lient à de multiples sarbecovirus
AU2022261268A1 (en) * 2021-04-22 2023-11-16 Guangdong Fapon Biopharma Inc. Bispecific multifunctional fusion polypeptide
WO2022233956A1 (fr) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant de manière spécifique à prame
AU2022273737A1 (en) 2021-05-14 2023-11-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
KR20240035758A (ko) 2021-05-24 2024-03-18 비르 바이오테크놀로지, 인코포레이티드 조작된 폴리펩타이드
US20240327492A1 (en) * 2021-07-29 2024-10-03 Nantcell, Inc. Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
WO2023034871A1 (fr) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Thérapies par anticorps à haute concentration contre infection par sars-cov-2
JP2024533166A (ja) 2021-09-01 2024-09-12 ヴィア・バイオテクノロジー・インコーポレイテッド 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
WO2023036137A1 (fr) * 2021-09-10 2023-03-16 Wuxi Biologics (Shanghai) Co. Ltd. Procédé de préparation de conjugués anticorps-médicament hautement homogènes pour anticorps modifiés
WO2023046093A1 (fr) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 Complexe polypeptidique bispécifique
US20240409618A1 (en) * 2021-10-13 2024-12-12 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
CN118574850A (zh) 2021-10-27 2024-08-30 维尔托索宾科公司 用于治疗cd47相关疾病的多特异性抗体
CA3240483A1 (fr) 2021-12-10 2023-06-15 Thomas Dudler Anticorps therapeutiques qui se lient au domaine serine protease de masp-2 et leurs utilisations
EP4489782A4 (fr) 2022-03-10 2026-03-25 Omeros Corp Inhibiteurs de masp-2 et masp-3, et compositions et méthodes associées pour le traitement de la drépanocytose
WO2023179370A1 (fr) * 2022-03-21 2023-09-28 The Hong Kong Polytechnic University Anticorps bispécifique peptidique, ses procédés de préparation et ses utilisations
KR20240162568A (ko) * 2022-03-25 2024-11-15 우시 바이올로직스 아일랜드 리미티드 항-her2/항-cd47 분자 및 이의 용도
WO2023201256A1 (fr) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. Thérapies par anticorps à haute dose contre une infection par le sars-cov-2
EP4524248A4 (fr) * 2022-05-12 2026-07-01 Astellas Pharma Inc Anticorps multispécifique anti-taa et anti-cd3
WO2023230448A1 (fr) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Immunothérapie combinée contre la grippe
US20260184814A1 (en) 2022-05-23 2026-07-02 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
WO2023245078A1 (fr) 2022-06-15 2023-12-21 Humabs Biomed Sa Anticorps anti-parvovirus et leurs utilisations
WO2023246911A1 (fr) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 Molécule polypeptidique bispécifique à base de récepteur de lymphocytes t et son utilisation
WO2024006472A1 (fr) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Anticorps qui se lient à de multiples sarbecovirus
JP2025526405A (ja) 2022-07-27 2025-08-13 ヒューマブス・バイオメッド・ソシエテ・アノニム Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
WO2024112818A1 (fr) 2022-11-22 2024-05-30 Humabs Biomed Sa Anticorps anti-sars-cov-2 modifiés et leurs utilisations
AU2023383819A1 (en) * 2022-11-24 2025-05-08 WuXi Biologics Ireland Limited Psma antibodies and uses thereof
WO2024118998A2 (fr) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Anticorps anti-sars-cov-2 modifiés et leurs méthodes d'utilisation
TW202446788A (zh) 2023-04-10 2024-12-01 美商維爾生物科技公司 結合多種薩貝冠狀病毒之抗體
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
WO2025010424A1 (fr) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Anticorps dirigés contre des antigènes de staphylococcus et leurs méthodes d'utilisation
EP4743488A1 (fr) 2023-07-13 2026-05-20 VIR Biotechnology, Inc. Anticorps largement neutralisants contre les paramyxovirus rsv et mpv
IL327059A (en) * 2023-09-11 2026-05-01 Shanghai Btd Bio Tech Co Ltd A long-acting fusion protein that is an agonist for the parathyroid hormone receptor, and its use
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025087436A1 (fr) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 Molécule polypeptidique multi-spécifique basée sur un récepteur de lymphocytes t, composition et utilisation associées
KR20260102788A (ko) * 2023-11-01 2026-07-01 이뮤노코어 리미티드 소형 멀티도메인 단백질의 정제 방법
CN117665160A (zh) * 2023-12-04 2024-03-08 浙江理工大学 一种提取皮革文物中胶原蛋白进行种属鉴定的方法
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12121587B1 (en) * 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
WO2025157168A1 (fr) * 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Focalisation isoélectrique capillaire imagée pour détecter un sous-produit de mésappariement dans des anticorps bispécifiques asymétriques
WO2025157223A1 (fr) * 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps multispécifiques et leurs utilisations
TW202545992A (zh) 2024-01-23 2025-12-01 中國大陸商上海藥明生物技術有限公司 靶向ｃｄ３、ｃｄ１９及ｃｄ２０之多特異性抗體及其用途
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
WO2026039642A1 (fr) 2024-08-16 2026-02-19 Ardeagen Corporation Conjugués d'anticorps anti-mésothéline et leurs procédés d'utilisation
WO2026043909A1 (fr) * 2024-08-19 2026-02-26 HCW Biologics, Inc. Polypeptides chimériques à chaîne unique et leurs utilisations
US20260132185A1 (en) * 2024-08-19 2026-05-14 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2026055183A1 (fr) 2024-09-03 2026-03-12 Vir Biotechnology, Inc Compositions antivirales et leurs méthodes d'utilisation
WO2026117540A1 (fr) 2024-11-27 2026-06-04 Vir Biotechnology, Inc. Anticorps anti-vih-1 et leurs utilisations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
PT1421115E (pt) * 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
EA006601B1 (ru) * 2001-08-31 2006-02-24 Авидекс Лимитед Растворимый рецептор т- клетки
EP2048159B1 (fr) * 2002-11-09 2014-01-01 Immunocore Ltd. Présentation de récepteur de lymphocyte T
GB0226227D0 (en) * 2002-11-09 2002-12-18 Avidex Ltd Receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
CA2558811A1 (fr) 2004-03-08 2005-09-22 Zymogenetics, Inc. Proteines de fusion dimeres et materiaux et methodes de production de ces proteines
WO2005113595A2 (fr) * 2004-05-19 2005-12-01 Avidex Ltd Recepteurs des lymphocytes t ny-eso a affinite elevee
WO2006054096A2 (fr) * 2004-11-18 2006-05-26 Avidex Ltd Proteines bifonctionnelles solubles
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
US9078843B2 (en) 2005-09-22 2015-07-14 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
EP2626372B1 (fr) 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
WO2013041865A1 (fr) 2011-09-22 2013-03-28 Immunocore Limited Récepteurs de lymphocytes t
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
CN105017422A (zh) 2014-04-30 2015-11-04 山东百因制药技术有限公司 一种抗cd3/抗cd19双特异性抗体及其应用
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
EA201790719A1 (ru) 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
MX384198B (es) 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
CN104829726B (zh) 2015-01-21 2019-03-05 武汉友芝友生物制药有限公司 一种双特异性抗体cd19xcd3的构建及应用
CN106279404A (zh) 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
EP3356407B1 (fr) * 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-cd19xcd3
WO2017059900A1 (fr) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Récepteurs antigéniques chimériques et leurs utilisations
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
CN106883298B (zh) 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 双特异性偶联抗体及其制法和用途
WO2017112944A1 (fr) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center Récepteurs des cellules t à forte affinité et leurs utilisations
WO2017192536A1 (fr) 2016-05-02 2017-11-09 University Of Kansas Élimination de la restriction par le cmh du récepteur de lymphocyte t en tant que stratégie d'immunothérapie
SG11201908783QA (en) * 2017-03-24 2019-10-30 Univ Leland Stanford Junior Antigen discovery for t cell receptors isolated from patient tumors recognizing wild-type antigens and potent peptide mimotopes
CN111108119B (zh) 2017-09-21 2022-11-15 上海药明生物技术有限公司 新型抗CD3ε抗体
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物

Also Published As

Publication number Publication date
MX2020003145A (es) 2020-07-29
CN117843810A (zh) 2024-04-09
MX2026003316A (es) 2026-05-04
AU2018334886A1 (en) 2020-04-09
IL310960A (en) 2024-04-01
PH12020550112A1 (en) 2020-10-26
EA202090812A1 (ru) 2020-08-07
SG11202002261VA (en) 2020-04-29
IL273217B1 (en) 2024-12-01
KR20250114570A (ko) 2025-07-29
KR20200055729A (ko) 2020-05-21
JP2024012612A (ja) 2024-01-30
TWI786188B (zh) 2022-12-11
IL273217A (en) 2020-04-30
IL273217B2 (en) 2025-04-01
ZA202002338B (en) 2024-09-25
WO2019057122A1 (fr) 2019-03-28
CA3075693A1 (fr) 2019-03-28
IL326091A (en) 2026-03-01
JP2020534034A (ja) 2020-11-26
BR112020005676A2 (pt) 2020-10-20
IL310960B1 (en) 2026-03-01
AU2025234294A1 (en) 2025-10-16
IL310960B2 (en) 2026-07-01
JP7387611B2 (ja) 2023-11-28
US20240124586A1 (en) 2024-04-18
US11845796B2 (en) 2023-12-19
KR102839644B1 (ko) 2025-07-31
EP3684805A1 (fr) 2020-07-29
MY202919A (en) 2024-05-29
JP2026108827A (ja) 2026-06-30
TW201915025A (zh) 2019-04-16
US20200283524A1 (en) 2020-09-10
EP3684805A4 (fr) 2021-06-09
JP7844420B2 (ja) 2026-04-13
CN111133003A (zh) 2020-05-08
CN111133003B (zh) 2024-01-12
SA522440090B1 (ar) 2025-05-06
AU2018334886B2 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
EP3684805A4 (fr) Nouveaux complexes polypeptidiques bispécifiques
IL269307B (en) Methods for cryogenic storage
MA50185A (fr) Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques
EP3416690A4 (fr) Aptamère bispécifique
EP3587675A4 (fr) Excavatrice
EP3733978A4 (fr) Excavatrice
EP3708718A4 (fr) Excavatrice
DK3608337T3 (da) Bispecifikke T-celleaktiverende antigenbindende molekyler
DK3668566T3 (da) Patch-pumpe
DK3365373T3 (da) Bindingsmolekyler, der hæmmer cancervækst
DK3313876T3 (da) Multispecifikke antigenbindende proteiner
IL269602B (en) Cryopreservation method
KR20180085002A (ko) 인간화된 항-cll-1 항체
EP3638335C0 (fr) Pompe à lait maternel
PL3242892T3 (pl) Zmienione przeciwciała wiążące april
EP3643842A4 (fr) Excavatrice
EP3594416A4 (fr) Pelleteuse
EP3722618A4 (fr) Excavatrice
EP3593139C0 (fr) Biomarqueurs du cancer
EP3693499C0 (fr) Tresse
IL283279A (en) Bi-specific conjugates
EP3725960A4 (fr) Pelleteuse
EP3591049A4 (fr) Variant du facteur (b) de limule
EP3591125A4 (fr) Excavatrice
DK3728328T3 (da) Bispecifik antigenbindende konstruktion